A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis (NCT06025578)

🧪 Interventions in This Study

• BMS-986278 (DRUG)
• BMS-986278 Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (459 Sites)

Showing the first 25 of 459 sites.

• Local Institution - 0046 — Birmingham, Alabama
• Local Institution - 0314 — Phoenix, Arizona
• Local Institution - 0336 — La Jolla, California
• Local Institution - 0212 — Los Angeles, California
• Local Institution - 0019 — Los Angeles, California
• Local Institution - 0535 — Newport Beach, California
• Local Institution - 0366 — Orange, California
• Local Institution - 0341 — Sacramento, California
• Local Institution - 0015 — San Francisco, California
• Local Institution - 0352 — Stanford, California
• Local Institution - 0321 — Aurora, Colorado
• Local Institution - 0376 — Denver, Colorado
• Local Institution - 0211 — New Haven, Connecticut
• Local Institution - 0418 — Stamford, Connecticut
• Local Institution - 0067 — Newark, Delaware
• Local Institution - 0354 — Washington D.C., District of Columbia
• Local Institution - 0195 — Brandon, Florida
• Local Institution - 0380 — Celebration, Florida
• Local Institution - 0013 — Clearwater, Florida
• Local Institution - 0396 — DeBary, Florida
• Local Institution - 0036 — Gainesville, Florida
• Local Institution - 0193 — Gainesville, Florida
• Local Institution - 0073 — Loxahatchee Groves, Florida
• Local Institution - 0220 — Ocala, Florida
• Local Institution - 0452 — Pensacola, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Progressive Pulmonary Fibrosis

• PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis — Aurora, Colorado
• Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) — Birmingham, Alabama
• SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers — Charleston, South Carolina
• An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) — Birmingham, Alabama

Explore by condition: All Progressive Pulmonary Fibrosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.